• Phosphotungstic Acid Negative Stain Solution: Evidence

  2026-10-07

  Phosphotungstic Acid Negative Stain Solution (2%) can provide high-contrast structural context across electron microscopy applications. This evidence-focused guide explains what negative staining can reveal, why it cannot directly prove glycan binding, and how to interpret viral imaging alongside mechanistic virology.

• Y-27632 Dihydrochloride in Pluripotency Research

  2026-10-07

  Y-27632 dihydrochloride is a selective ROCK inhibitor whose value in stem cell research extends beyond simple survival effects. This article examines how ROCK signaling can be interpreted alongside the 2025 KLF7 pluripotency study, distinguishing cytoskeletal support from genuine changes in cell state.

• Y-27632 Dihydrochloride and Cell Adhesion

  2026-10-06

  Y-27632 dihydrochloride is a selective ROCK inhibitor whose effects on contractility, junction organization, and stem cell survival can clarify interspecies cell-adhesion research. This evidence-focused analysis connects ROCK signaling with the 2024 Cell Stem Cell study while distinguishing pharmacological modulation from synthetic adhesion engineering.

• Tetracycline Hydrochloride: Evidence and Applications

  2026-10-06

  A source-grounded overview of Tetracycline Hydrochloride, including its antibacterial mechanism, reported activity against Staphylococcus aureus and acne-associated bacteria, skin microbiome considerations, evidence limitations, and distinction from emerging platinum-based cancer therapeutics.

• CK2 Phosphorylation Tunes LOH2 and Plant Immunity

  2026-10-05

  Zhang et al. show that CK2 phosphorylation creates a regulatory trade-off in the Arabidopsis ceramide synthase LOH2: it increases catalytic activity and substrate affinity while also promoting polyubiquitination and proteasomal turnover. The work connects this post-translational control to C16 ceramide accumulation, salicylic acid signaling, cell death, and resistance to biotic stress, establishing a mechanistic framework for phosphorylation-dependent control of plant sphingolipid metabolism.

• TSPAN18–STIM1 Axis in Prostate Cancer Bone Metastasis

  2026-10-05

  Zhou et al. identify TSPAN18 as a regulator of STIM1 stability and show that protection from TRIM32-mediated ubiquitination strengthens calcium signaling associated with prostate cancer bone metastasis. The study provides a mechanistic link between protein turnover, store-operated calcium entry, metastatic behavior, and clinical disease associations, while leaving therapeutic translation to future validation.

• TUNEL Evidence in Neonatal Sevoflurane Neurotoxicity

  2026-10-04

  A source-grounded overview of how TUNEL-based DNA fragmentation detection was used in a neonatal mouse study of sevoflurane neurotoxicity, with attention to FITC-labeled dUTP incorporation, evidence strength, interpretation limits, and the boundaries of translating apoptosis findings to human health.

• HEV Organoids Reveal Pan-Tissue Infection

  2026-10-03

  A 2025 Gut study developed induced pluripotent stem cell-derived liver, intestinal, and brain organoids that supported propagation of HEV genotypes 1, 3, and 4. The models revealed cell-type-specific infection, organ injury phenotypes, and partial response to ribavirin, providing a physiologically richer platform for studying HEV pathogenesis and antiviral responses.

• Flavopiridol A3417: Reliable CDK Assays

  2026-10-01

  Flavopiridol (SKU A3417) offers a practical, mechanistically defined approach to studying CDK-dependent proliferation, cell-cycle arrest, and cytotoxicity. This scenario-based guide explains formulation, dose planning, interpretation, ER-stress comparisons, and vendor-selection criteria for more defensible cancer research workflows.

• Toremifene Workflows for Prostate Cancer Research

  2026-10-01

  Toremifene enables controlled interrogation of estrogen receptor biology alongside growth, migration, and calcium-signaling readouts. This workflow-focused guide shows how to connect SERM pharmacology with the TSPAN18–STIM1 metastasis model without overstating an unproven direct mechanism.

• Telmisartan in Cardiac Hypertrophy Assay Design

  2026-09-30

  Telmisartan is an angiotensin II receptor antagonist useful for separating AT1R-driven remodeling from downstream RIP3/CaMKII signaling in cardiac hypertrophy models. This article translates recent mechanistic findings into a decision framework for cardiovascular disease research, assay controls, and compound handling.

• Degarelix Acetate in Prostate Cancer Therapy

  2026-09-30

  The 2009 review by Laurence Klotz describes Degarelix acetate as a third-generation GnRH receptor antagonist that suppresses androgen signaling without the testosterone surge associated with GnRH agonists. Its clinical importance lies in rapid testosterone and prostate-specific antigen responses, a monthly subcutaneous formulation, and a safety profile considered comparable with established agonist therapy at the time of publication.

• Oral Dextran Microgels for Local Colon Cancer Therapy

  2026-09-29

  The reference study develops an orally administered, sequentially targeted system that combines dextran microgels with cisplatin/SPION lipid nanoparticles for localized colon cancer treatment. Its design links colon-specific enzymatic release, folate-receptor-mediated uptake, and magnetic hyperthermia to improve tumor control while limiting systemic exposure.

• Vitamin C Workflows for Cancer and HEV Organoids

  2026-09-29

  Build reproducible ascorbic acid dose–response workflows for tumor-cell assays while using multilineage organoids to test tissue-specific injury and host responses. The approach separates established anticancer evidence from exploratory HEV applications, helping researchers avoid mistaking general cytotoxicity for antiviral activity.

• AR and ARv7 in TNBC: EPI-001 Study Insights

  2026-09-28

  This 2025 study links androgen receptor (AR) and AR splice variant 7 (ARv7) expression with unfavorable outcomes and metastatic risk in triple-negative breast cancer (TNBC). In MDA-MB-231 cells, pharmacologic targeting with enzalutamide or the androgen receptor N-terminal domain inhibitor EPI-001 altered migration- and epithelial-to-mesenchymal transition-associated markers, supporting ARv7-focused investigation in TNBC.

8569 records 1/572 page Next 12345 下5页 Last page